China Pharma Holdings (CPHI) Operating Income (2016 - 2025)
Historic Operating Income for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$628145.0.
- China Pharma Holdings' Operating Income rose 4212.02% to -$628145.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 2932.72%. This contributed to the annual value of -$4.6 million for FY2024, which is 6675.75% down from last year.
- Latest data reveals that China Pharma Holdings reported Operating Income of -$628145.0 as of Q3 2025, which was up 4212.02% from -$652120.0 recorded in Q2 2025.
- In the past 5 years, China Pharma Holdings' Operating Income ranged from a high of -$397479.0 in Q1 2023 and a low of -$1.4 million during Q2 2024
- Over the past 5 years, China Pharma Holdings' median Operating Income value was -$758618.0 (recorded in 2025), while the average stood at -$831002.9.
- As far as peak fluctuations go, China Pharma Holdings' Operating Income plummeted by 110413.15% in 2021, and later skyrocketed by 5640.33% in 2023.
- China Pharma Holdings' Operating Income (Quarter) stood at -$648690.0 in 2021, then tumbled by 80.21% to -$1.2 million in 2022, then fell by 1.32% to -$1.2 million in 2023, then dropped by 0.97% to -$1.2 million in 2024, then soared by 47.48% to -$628145.0 in 2025.
- Its Operating Income was -$628145.0 in Q3 2025, compared to -$652120.0 in Q2 2025 and -$758618.0 in Q1 2025.